# Safety and Tolerability Study of CTx1000 In Participants With Amyotrophic Lateral Sclerosis

> **NCT07401121** · PHASE1 · RECRUITING · sponsor: **Celosia Therapeutics Pty Ltd** · enrollment: 15 (estimated)

## Conditions studied

- ALS (Amyotrophic Lateral Sclerosis)

## Interventions

- **DRUG:** AAV9 Gene therapy

## Key facts

- **NCT ID:** NCT07401121
- **Lead sponsor:** Celosia Therapeutics Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-12
- **Primary completion:** 2027-12
- **Final completion:** 2030-12
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07401121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07401121, "Safety and Tolerability Study of CTx1000 In Participants With Amyotrophic Lateral Sclerosis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07401121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*